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“Acute” West Nile
Virus Encephalitis
(Response to
Krishnamoorthy 
et al.)
To the Editor: In a letter to the
editor, Krishnamoorthy et al. question
the diagnosis of “acute West Nile
encephalitis” in our case report. We
did not use the word “acute” in the
paper, but the patient did in fact have
an acute illness. We believe that this
case report, in which West Nile virus
(WNV) was isolated in cell culture,
represents the best evidence for a
WNV infection in a human in the
United States. The diagnosis of West
Nile encephalitis was based on clini-
cal analysis (1); not everyone with the
diagnosis undergoes an autopsy. In
many instances, patients do recover.
In our case, the patient had the clinical
features of encephalitis consisting of
unremitting fever associated with a
rapid course of progressive confusion
and lethargy followed by coma. In
addition, increased depression of res-
piratory drive existed, pointing to
brain stem involvement. We agree that
the inflammatory changes in the brain
were limited as compared to such
changes in other reported cases of
WNV; however, this limitation was
attributable to the fact that the patient
was both immunocompromised and
neutropenic at the time of acute infec-
tion. Therefore, the usual inflammato-
ry response cannot be expected. Even
though the changes were limited, they
were consistent with the histologic
findings in previously published
reports (1,2).
The second point by Krishna-
moorthy et al. represents their hypoth-
esis about a human chronic carrier
state for WNV. Although a chronic
carrier state is possible, the viremic
period associated with arboviral
infections is typically short (3). While
one cannot rule out persistent infec-
tion with WNV, until our report
attempts to recover the virus by isola-
tion in North America in humans have
been uniformly unsuccessful. Also,
previous reports of successful WNV
isolations by Israeli investigators in
immunocompetent hosts (4) have
been from blood specimens before
seroconversion. These considerations
indicate that the virus is not routinely
found in the blood in substantial
amounts by the time clinical symp-
toms consistent with WNV infection
occur. We do not know, nor have we
speculated, about the timing of the
infection as the patient had no recol-
lection of a mosquito bite. Tests for
both immunoglobulin (Ig) G and IgM
antibodies to WNV were negative in
our patient. Because the patient was
immunocompromised, a humoral
response was not expected; therefore,
this information cannot be used asevidence that the patient had an acute
infection. However, observations that
the patient had no manifestation of
encephalitis during a previous episode
of neutropenia and that she had an
acute febrile illness associated with
neurologic signs of encephalitis point
to an acute infection. The figure, in
which WNV copy numbers are corre-
lated with leukocyte count, is not
intended to pinpoint the time of infec-
tion. However, as stated in the paper,
this figure did show that the virus was
rapidly cleared after resolution of
neutropenia.
A report by Camenga et al. (5)
demonstrated that mice, infected with
WNV develop only an inapparent
infection. These mice will invariably
die of fulminant encephalitis if only a
single dose of cyclophosphamide is
given. However, mice treated with
one dose of cyclophosphamide
demonstrate inflammatory changes in
the brain. If a second dose of the drug
is administered 5 days after infection,
inflammation is completely sup-
pressed in mice. Although mice are
immunologically different from
humans, this work, done almost 30
years ago, supports the argument for
an acute infection in the current case
report. If the patient in our study was
a chronic carrier, she should have had
manifestations of acute West Nile
encephalitis immediately following
the first course of combination
chemotherapy, which was much more
immunosuppressive than cyclophos-
phamide alone. This fact reempha-
sizes our major point in the article that
patients who are immunocompro-
mized and undergoing chemotherapy,
which may cause neutropenia, should
take extra precautions against being
exposed to WNV. 
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Correction Vol. 9, No. 4
In the article, “Antimicrobial Drug Prescriptions in Ambulatory Care Settings,
United States, 1992–2000” by Linda F. McCaig et al. errors occurred on pages
432, 434, and 446. On page 432, the correct affiliations are as follows: Linda F.
McCaig, National Center for Health Statistics, Centers for Disease Control and
Prevention (CDC), Hyattsville, Maryland, USA; Richard E. Besser and James M.
Hughes, National Center for Infectious Diseases, CDC, Atlanta, Georgia, USA.
In the abstract, the change in antimicrobial prescribing rate for amoxicillin/clavu-
lanate is +69%. On page 434, second paragraph, Results section, the correct first
sentence appears below:
During the study period, the antimicrobial prescribing rate at all ambulatory
care visits declined for amoxicillin and ampicillin (–43%; p<0.001),
cephalosporins (–28%; p<0.001), and erythromycin (–76%; p<0.001) (Figure 5);
the prescribing rate rose for azithromycin and clarithromycin (+388%; p<0.001),
quinolones among persons >15 years (+78%; p<0.001), and amoxicillin/clavu-
lanate  (+69%; p=0.004) (Figure 6). 
On page 436, the correct caption to Figure 6 appears below:
Trends in increasing annual antimicrobial prescribing rates by drug class—
United States, 1992–2000. Note: trend for amoxicillin/clavulanate p<0.001; for
quinolones among persons >15 years, p<0.001; for azithromycin and clar-
ithromycin among all ages, p<0.001.
The corrected article appears online at http://www.cdc.gov/ncidod/EID/
vol9no4/02-0268.htm. 
We regret any confusion these errors may have caused.
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